[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"UConn Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":469},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,45,75,103,123,144,165,187,210,235,263,304,325,346,363,388,413,441],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100581172","phase-4-gadopiclenol-vs-gadobutrol-for-dynamic-contrast-enhanced-pituitary-mri-magnetic-resonance-imaging-100581172",false,"NCT06846853","Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging)","Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI: A Pilot Study","MRI","Inclusion criteria:\n\n1. Male adult patient who is at 18 years old or above, or female adult patient who is at 55 years old or above.\n2. Patient presenting with known or highly suspected pituitary lesion(s) with focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors) based on results of a previous imaging procedure such as Computed Tomography (CT) or MRI, which should have been performed within 12 months prior to informed consent form signature.\n3. Patient scheduled for a contrast-enhanced MRI examination with a focus on pituitary for clinical reasons and agreeing to have a second contrast-enhanced MRI examination for the purpose of the trial.\n4. If the patient was treated (either with radiation, surgery, biopsy or other relevant treatments) for a pituitary condition between previous imaging evaluation and trial MRI, there should still be a high suspicion of remaining lesion(s) on the basis of available clinical information.\n5. Patient able and willing to participate in the trial.\n6. Patient having read the information and having provided his\u002Fher consent to participate in writing by dating and signing the informed consent prior to any trial related procedure being conducted.\n7. Patient affiliated to national health insurance according to local regulatory requirements.\n\nExclusion criteria:\n\n1. Patient presenting with known class III\u002FIV congestive heart failure according to the New York Heart Association classification (NYHA).\n2. Patient having received any investigational medicinal product within 7 days prior to trial entry or scheduled to receive any investigational treatment in the course of the trial.\n3. Patient presenting with any contraindication to MRI examinations.\n4. Patient previously randomized in this trial.\n5. Patient having received any contrast agent (MRI or CT) within 3 days prior to first trial product administration, or scheduled to receive any contrast agent during the course of the trial or within 24 hours after the second trial product administration\n6. Patient expected\u002Fscheduled to have any treatment or medical procedure (e.g. chemotherapy, radiotherapy, biopsy or surgery etc.) that may impact the aspects of the imaged lesions between the 2 MRI examinations. (Patients under corticosteroids and\u002For maintenance chemotherapy with a stable dose at the time of screening visit and throughout the trial can be included).\n\nPatient with anticipated, current or past condition (medical, psychological, social or geographical) that would compromise the patient's safety or her\u002Fhis ability to participate in the trial.\n\n8\\. Patient unlikely to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits and\u002For unlikelihood of completing the trial.\n\n9\\. Patient related to the investigator or any other trial staff or relative directly involved in the trial conduct. 10. Patient presenting with acute or chronic renal insufficiency, defined as an estimated Glomerular Filtration Rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m² assessed within 1 day prior to each contrast agent injection. 11. Patient with known contra-indication(s) to the use or with known sensitivity to one of the products under investigation or to other GBCAs (such as hypersensitivity, post contrast acute kidney injury).\n\n12\\. Patient who are prisoners, pregnant women, or educationally disadvantaged persons known as vulnerable population will be excluded as well to protect the rights and welfare of these participants.","ALL","19 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study will evaluate the efficacy and safety of Gadopiclenol, an FDA-approved contrast agent, for visualizing pituitary lesions on MR images by comparing with the comparator, Gadobutrol, a clinically widely used contrast agent. The study is double-blinded, so neither the participants nor the researchers know which contrast agent is being used during each scan to avoid the bias of results.",[27,28],"Contrast Enhanced Images vs. Non-contrast Images","Gadopiclinol Enhanced Images vs. Gadobutrol Enhanced Images",[30,31],"Gadobutrol enhanced images","Gadopiclinol enhanced images","RECRUITING","2026-04-24",{"date":35,"type":36},"2026-04-28","ACTUAL",{"date":38,"type":36},"2025-03-25",{"date":40,"type":21},"2026-06-30",{"name":42,"class":43},"UConn Health","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100597726","a-randomized-clinical-trial-comparing-embryo-euploidy-rates-following-ultrashort-versus-standard-abstinence-100597726","NCT07062237","A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence","A Double-Blinded Prospective Randomized Clinical Trial Comparing Euploidy Rates Among Embryos Created From Sibling Oocytes Exposed to Sperm After Ultrashort Abstinence Compared With Standard Abstinence","Inclusion Criteria:\n\n* Subjects are nonpregnant females ≥ 18 years and ≤ 42 years of age.\n* Subjects obtain greater than or equal to 6 mature oocytes at the time of oocyte retrieval for ICSI or greater than or equal to 8 oocytes at the time of oocyte retrieval for standard insemination.\n* Subjects are utilizing standard insemination or ICSI for fertilization.\n* Subjects are undergoing PGT-A (PGT for aneuploidy) or PGT-M (PGT for monogenic disorders).\n* Subjects are willing to comply with study protocol and procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Subjects are utilizing donor oocytes, donor sperm, or gestational carrier.\n* Subjects have a diagnosis of cryptozoospermia (no spermatozoa identified in fresh semen sample).\n* Subjects are utilizing surgically removed sperm (e.g. via testicular sperm aspiration \\[TESA\\] or microsurgical epididymal sperm aspiration \\[MESA\\]).\n* Subjects are utilizing frozen\u002Fthawed sperm, including in cases in which a fresh sample was planned and the sample is insufficient for use.\n* Subjects are utilizing frozen\u002Fthawed oocytes.\n* Subjects undergoing PGT-SR (PGT for structural rearrangements).\n* Subjects are undergoing a day 3 (cleavage stage) embryo transfer.\n* Subjects obtain less than 6 mature oocytes at the time of oocyte retrieval for ICSI or less than 8 oocytes at the time of oocyte retrieval for standard insemination.\n* Subjects obtain greater than or equal to 6 mature oocytes at the time of oocyte retrieval for ICSI or greater than or equal to 8 oocytes at the time of oocyte retrieval for standard insemination but choose to fertilize fewer than 6 (for ICSI) or 8 (for standard insemination).\n* Male partner is unable to produce a second semen sample within three hours of the first semen sample (standard abstinence sample)\n* Male partner has an infectious disease.","18 Years","42 Years",{"count":55,"type":21},187,[57],"NA","This research is being done to determine if producing sperm after an ultrashort period of abstinence (1 hour of abstinence) will be effective in improving the rates of embryos with normal chromosomes (structures that carry genetic information) during in vitro fertilization (IVF) treatment. The investigators hypothesize that a shorter period of abstinence is effective at improving rates of normal chromosomes among embryos.",[60,61],"Infertility","Male Factor Infertility",[63,64,65,66],"Ultrashort abstinence","Sibling oocyte","In vitro fertilization","Euploid embryos","2026-04-16",{"date":69,"type":36},"2026-04-21",{"date":71,"type":36},"2025-07-27",{"date":73,"type":21},"2027-06",{"name":42,"class":43},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":44},"100180989","genetic-and-functional-analysis-of-craniometaphyseal-dysplasia-cmd-100180989","NCT01630460","Genetic and Functional Analysis of Craniometaphyseal Dysplasia (CMD)","Identification of Mutations That Lead to Craniometaphyseal Dysplasia in Families and Isolated Cases and Studies of Cellular and Molecular Mechanisms","CMD","Inclusion Criteria:\n\n* CMD; unaffected individuals only if part of a participating CMD family\n\nExclusion Criteria:\n\n* No CMD; unaffected individuals only as part of a participating CMD family",{"count":84,"type":21},600,"OBSERVATIONAL","CMD can be inherited in an autosomal dominant or recessive trait. CMD may also be caused by de novo mutations. The goal of this study is to identify genes and regulatory elements on chromosomes that are the cause for CMD. The investigators also study blood samples and tissue samples from patients to learn about the processes that lead to this disorder. The investigators long-term goal is to find mechanisms to slow down bone deposition in CMD patients.",[88],"Craniometaphyseal Dysplasia",[90,91,92,93,94],"Craniometaphyseal dysplasia","bone","hyperostosis","osteoblast","osteoclast","2026-04-14",{"date":97,"type":36},"2026-04-17",{"date":99,"type":4},"2009-04",{"date":101,"type":21},"2030-12",{"name":42,"class":43},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":121,"leadSponsor":122,"locationsCount":44},"100180986","genetic-and-functional-analysis-of-aplasia-cutis-congenital-acc-100180986","NCT01630421","Genetic and Functional Analysis of Aplasia Cutis Congenital (ACC)","Identification of Mutations That Lead to Aplasia Cutis Congenita in Families and Isolated Cases and Studies of Cellular and Molecular Mechanisms","ACC","Inclusion Criteria:\n\n* ACC; unaffected individuals only if part of a participating ACC family\n\nExclusion Criteria:\n\n* No ACC unaffected individuals only as part of a participating ACC family",{"count":84,"type":21},"The goal of this research study is to identify genes and regulatory elements on chromosomes that cause ACC. The investigators also study tissue samples from patients to learn about the processes that lead to this disorder.",[114],"Aplasia Cutis Congenita",[116,91,93,94,117],"Aplasia cutis congenita","skin",{"date":119,"type":36},"2026-04-15",{"date":99,"type":4},{"date":101,"type":21},{"name":42,"class":43},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":143,"locationsCount":44},"100180988","genetic-and-functional-analysis-of-cherubism-100180988","NCT01630447","Genetic and Functional Analysis of Cherubism","Identification of Mutations That Lead to Cherubism in Families and Isolated Cases and Studies of Cellular and Molecular Mechanisms","CBM","Inclusion Criteria:\n\n* cherubism; unaffected individuals only if part of a participating cherubism family\n\nExclusion Criteria:\n\n* no cherubism unaffected individuals only as part of a participating cherubism family",{"count":84,"type":21},"The goal of this research study is to identify genes and regulatory elements on chromosomes that cause cherubism. Together with the investigators collaborators the investigators also study blood samples and tissue samples from patients to learn about the processes that lead to this disorder. The long-term goal of researchers involved in this study is to find mechanisms to slow down bone resorption in cherubism patients.",[134],"Cherubism",[136,91,137,93,94,138,139],"cherubism","autoinflammatory disorder","mandible","maxilla",{"date":119,"type":36},{"date":99,"type":4},{"date":101,"type":21},{"name":42,"class":43},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":164,"locationsCount":44},"100180154","genetic-analysis-of-keloids-100180154","NCT01619553","Genetic Analysis of Keloids","Identification of Genetic Variants That Contribute to Keloid Formation in Families and Isolated Cases.","Inclusion Criteria:\n\n* keloids;\n* unaffected individuals only if part of a participating keloid family\n\nExclusion Criteria:\n\n* no keloids;\n* unaffected individuals only as part of a participating keloid family",{"count":152,"type":21},7000,"Keloids have a strong genetic component. The goal of this study is to identify genes and regulatory elements on chromosomes that are the cause for keloids or contribute to keloid scarring.",[155],"Keloid",[157,158,159,160],"keloid","fibrosis","wound healing","scar",{"date":119,"type":36},{"date":99,"type":4},{"date":101,"type":21},{"name":42,"class":43},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":44},"100572322","phase-2-novel-approaches-to-the-treatment-of-hypothyroidism-100572322","NCT06731764","Novel Approaches to the Treatment of Hypothyroidism","Inclusion Criteria:\n\nHistory of hypothyroidism Treatment with levothyroxine Levothyroxine dose \\>1.2 mcg\u002Fkg\n\nExclusion Criteria:\n\nBody weight \\\u003C50 or \\>100 Kg.\n\nIndication for TSH suppression (high risk follicular-derived thyroid cancer).\n\nSecondary (pituitary) hypothyroidism (ICD-10 E23.0); Pregnancy; breastfeeding; uncontrolled diabetes (HbA1c \\>8.5% at screening); use of oral Semaglutide (Rybelsus); Uncontrolled Hypertension (BP \\> 140\u002F90 at screening); current use of T3-containing therapies (Liothyronine, desiccated thyroid extracts).\n\nPatients receiving lipid-lowering therapies must maintain the same dose throughout the participation in the study. Changes in lipid lowering therapy\u002Fdose will result in termination from the study.\n\nPatients receiving anti-acid (H2 blockers, proton pump inhibitors) therapies must maintain the same dose throughout the participation in the study. Changes in anti-acid therapy\u002Fdose will result in termination from the study. Use of other medications known to interfere with the absorption of thyroid hormone, or affecting the thyroid hormone axis (Burch 2019) will be considered exclusion criteria.\n\nBariatric surgery, initiation of GLP-1 agonist therapy (irrespective of the indication), enrollment in structured weight loss programs will result in dismissal from the study.\n\nCurrent pregnancy, pregnancy planned within the next 6 months, and lack of contraception in women of reproductive age will be exclusionary. We will verify that the participant is not pregnant through a urine pregnancy test at the time of the first study visit and at each of the follow-up visits. Any participants who become pregnant will terminate the study.",{"count":172,"type":21},90,[174,175],"PHASE2","PHASE3","Hypothyroidism is a common condition, more frequent in females, associated with excess of cardiovascular risk and poor quality of life not completely abrogated by treatment with levothyroxine.\n\nThere is an unmet need to define a safe, effective, and feasible regimen to be applied in large trials aimed at assessing levothyroxine\u002Fliothyronine combination therapy in patients living with hypothyroidism.\n\nTo address this knowledge gap we propose a randomized, three-arm, double-blind, controlled, escalating dose parallel pilot study whose results will lay the foundation of large multicenter trial(s) able to demonstrate the effectiveness (or lack thereof) of levothyroxine\u002Fliothyronine combination therapy.",[178],"Hypothyroidism","2026-03-17",{"date":181,"type":36},"2026-03-19",{"date":183,"type":36},"2024-12-10",{"date":185,"type":21},"2028-06-30",{"name":42,"class":43},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":195,"sex":17,"minAge":52,"maxAge":18,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":44},"100524939","partnering-to-enhance-emerging-adults-response-to-programs-100524939","NCT06115252","Partnering to Enhance Emerging Adults' Response to Programs","Partnering to Enhance Emerging Adults' Response to Programs (PEER)","PEER","Inclusion Criteria:\n\n* within the specified age range\n* agree to be contacted for the 3, 6, and 12 month follow ups\n* provide fully informed consent\n\nExclusion Criteria:\n\n* left-handed\n* evidence of brain injury\u002Fillness and\u002For neurological, neurodevelopmental disorder including psychosis and related medications (e.g., antipsychotics; neuroleptics)\n* loss of consciousness ≥ 2 minutes\n* other fMRI contraindications (e.g., unremovable metal on\u002Fin body, pregnant)",true,{"count":197,"type":21},248,[57],"The goal of this clinical trial (CT) is to learn more about emerging adults' and their peers. Here, we will see how co-participating with a peer in health program might impact brain and behavior change over time.\n\nEligible youth will be invited to come in for a \"Participation Day,\" during which they and a peer will independently complete questionnaires. With a peer, they will then complete a short health program, and undergo a brain scan (fMRI) while completing activities. Our study team will reach out to each participant individually again 3, 6, and 12 months later to learn about health behaviors over time.",[201],"Alcohol Use, Unspecified","2026-02-06",{"date":204,"type":36},"2026-02-10",{"date":206,"type":36},"2025-10-10",{"date":208,"type":21},"2028-03-31",{"name":42,"class":43},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":195,"sex":17,"minAge":217,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":44},"100518208","phase-2-the-mito-frail-trial-effects-of-mitoq-on-vasodilation-mobility-and-cognitive-performance-in-frail-older-adults-100518208","NCT06027554","The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults","Mito-Frail","Inclusion Criteria:\n\n* men and women aged 65-80 with a slow gait speed (0.4m\u002Fs based on a 4m walk) and\u002For mild cognitive impairment.\n* good cardiovascular health (not taking any blood pressure\u002Fflow\u002Fmetabolism altering medications)\n\nExclusion Criteria:\n\n* A vaccination in past two weeks\n* Recent acute infection three weeks prior to enrollment\n* Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy\n* Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids\n* Severe autoimmune disease requiring biological therapy\n* Major severe illness and\u002For Hospitalization in past 3 months\n* On warfarin or other medications that are considered a blood thinner\n* Recent fall or other conditions that will impair ability to complete and\u002For interpret mobility performance test\n* Known bleeding disorder\n* Any conditions that would impair the function to perform grip strength test\n* include advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, unintentional weight loss in last 12 months and participation in another study.\n* Diabetes patients requiring insulin (For reducing the risk that participants will have hypoglycemic episodes when fasting for study visits)\n* Baseline ECG QTc \\>450 ms in men and QTc \\>460 ms in women\n* Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)","65 Years","80 Years",{"count":220,"type":21},60,[174],"The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and\u002For cognitive dysfunction. The main question\\[s\\] it aims to answer are:\n\n* To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction\n* To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels\n* To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.",[224,225,226],"Frailty","Mild Cognitive Impairment","Aging","2026-01-08",{"date":229,"type":36},"2026-01-09",{"date":231,"type":36},"2024-10-07",{"date":233,"type":21},"2028-02-01",{"name":42,"class":43},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":243,"maxAge":218,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":44},"100452656","beta-blocker-discontinuation-in-heart-failure-with-preserved-ejection-fraction-100452656","NCT05174351","Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction","Effect of Beta-blocker Discontinuation on Functional Capacity and Cardiac Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction","HFpEF-BB","Inclusion Criteria:\n\n* Stable HFpEF patients with NYHA Class II-III or elevated BNP ≥100\n* N=30 (Target: 30).\n* Age: 50 \\~ 80 years.\n* ECHO evidence of EF ≥50% and Grade 2 or 3 diastolic dysfunction.\n* Chronic loop diuretic use\n* Currently on beta-blocker\n\nExclusion Criteria:\n\n* Beta blocker was prescribed for treating other cardiac conditions such as atrial fibrillation or coronary artery disease.\n* Heart rate \\> 100 bpm\n* Recent hospitalization due to HF within 3 months\n* Non-English speaker","50 Years",{"count":245,"type":21},30,[57],"This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.",[249],"Heart Failure With Preserved Ejection Fraction",[251,252,253,254],"HFpEF","Beta-blocker","echocardiogram","6MWT","2025-09-23",{"date":257,"type":36},"2025-09-29",{"date":259,"type":36},"2021-12-20",{"date":261,"type":21},"2027-11-01",{"name":42,"class":43},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":277,"overallStatus":295,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":44},"100408407","opioid-package-prototype-opp-100408407","NCT04598074","Opioid Package Prototype (OPP)","The Feasibility and Effectiveness of an Opioid Package Prototype (OPP) to Impact Opioid Prescribing, Dispensing, and Patient Use Outcomes","Inclusion Criteria:\n\n1. The patient is 18 years and older;\n2. The patient is one of the participating surgeons;\n3. The patient is receiving orthopaedic surgery that involves the use of opioid medication for post-operative pain;\n4. The patient is willing to receive oxycodone medication;\n5. The patient is willing and able to receive medication at the UConn Health Specialty Pharmacy, located in the Exchange across the street from the main entrance of UConn Health;\n6. The patient is willing and able to use a MyChart account;\n7. The patient is able to read and understand English; and\n8. The patient is able to understand the study procedures and their involvement in the study.\n\nExclusion Criteria:\n\n\\-",{"count":271,"type":21},352,[57],"The overall objective of this clinical trial is to identify the impact of selected package features, known as the Opioid Package Prototype (OPP), on the safe and effective use of opioids. Our specific aims are: (Aim 1) to evaluate the effectiveness of OPP on prescribing, dispensing, and patient use of oxycodone among orthopaedic surgery patients receiving post-operative outpatient oxycodone for post-surgical pain management, and (Aim 2) to determine the feasibility of OPP for orthopaedic surgery prescribers, pharmacists, and orthopaedic surgery patients. Such data can be used to further optimize packaging and labeling design, help patients and caregivers utilize their medication and packaging correctly, and improve prescribing and dispensing habits. The central hypothesis is that the OPP will be more effective than the amber vial in efforts to reduce oxycodone prescribing among patients over 18 receiving short-term management of post orthopedic surgery pain.",[275,276],"Opioid Use","Opioid Prescribing, Dispensing, and Patient Use",[278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294],"oxycodone","opioid","opioids","package","packaging","post-surgical pain","post-operative pain","orthopedic","orthopaedic","surgery","dispensing","prescribing","blister","tablets","pain","opioid package prototype","OPP","NOT_YET_RECRUITING","2025-08-29",{"date":298,"type":36},"2025-09-05",{"date":300,"type":21},"2025-09-07",{"date":302,"type":21},"2026-09-30",{"name":42,"class":43},{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":195,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":44},"100387190","study-of-circulating-monocytes-in-patients-with-ischemic-vascular-disease-100387190","NCT04321512","Study of Circulating Monocytes in Patients With Ischemic Vascular Disease","Inclusion Criteria:\n\n* STEMI Patients: Men and women aged 18 years and over, with symptoms, physical signs and ECG changes characteristic of STEMI.\n* NSTEMI Patients: Men and women aged 18 years and over, with symptoms, physical signs and ECG changes characteristic of NSTEMI.\n* Stable CAD Patients: men and women aged 18 years and older with coronary artery disease proven by prior MI history, angiography or stress test but without any unstable angina or acute coronary syndrome.\n* Ischemic Stroke Patients: Men and women aged 18 years and over, with symptoms, physical signs and CT\u002FMRI changes characteristic of ischemic stroke.\n* Healthy Controls: Men and women aged 18 years and over, without heart failure, coronary disease, hypertension, diabetes or other chronic diseases. Control subjects will be recruited from within the community of UConn Health via advertisement.\n\nExclusion Criteria:\n\n* Subjects who are unable to give informed consent (with the exception of the ischemic stroke arm patients, see Protocol Design below) and pregnant subjects.\n* Subjects who had any history of embolic, ischemic or hemorrhagic stroke within the last 12 months.",{"count":311,"type":21},300,"The purpose of this research study is to discover the functions of circulating white blood cells, called monocytes, and associated circulating substances in heart attack and ischemic stroke patients. Ischemic Strokes (clots) occur as a result of an obstruction within a blood vessel supplying blood to the brain. A type of monocyte carrying a surface marker called \"P2X4\" helps the immune system sense and respond to danger signals from the body such as heart muscle and brain tissue injuries.\n\nThe researchers expect to learn more about how these monocyte cells react to heart and brain tissue injury, and how the cells may then produce proteins or other chemical substances which promote the healing of heart muscle after heart attack and brain tissue after an ischemic stroke.",[314,315,316],"Myocardial Infarction","Stroke, Ischemic","Ischemia","2025-08-10",{"date":319,"type":36},"2025-08-14",{"date":321,"type":36},"2013-12-01",{"date":323,"type":21},"2027-12-01",{"name":42,"class":43},{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":333,"conditions":334,"keywords":337,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":44},"100114971","circulating-markers-that-underlie-the-transition-from-compensated-hypertrophy-to-heart-failure-100114971","NCT00762008","Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure","Inclusion Criteria:\n\n* Individuals aged \\>18yrs\n* stable or decompensated heart failure, irrespective of LVEF\n* decompensated heart failure clinical symptoms such as dyspnea, rales, edema, elevated jugular venous pressure, or ascites\n* Imaging evidence of heart failure (cardiomegaly, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures)\n* Healthy individuals with no prior history of heart attack or heart failure will be recruited to use as controls.\n\nExclusion Criteria:\n\n* Subjects who are unable to give informed consent\n* Subjects who had undergone cardiac or non-cardiac surgery in the 3 months before enrollment\n* Pregnant subjects are not excluded",{"count":332,"type":21},500,"The purpose of this research is to determine if two proteins in the blood are increased during acute heart failure. These two proteins are produced when the heart becomes dysfunctional and unable to contract normally. They may then be released into the blood and be detected by standard method in the research laboratory. Thus, the purpose of this study is to determine the relation between the change of these two proteins in the blood and the occurrence of acute heart failure. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or heart failure.",[335,336],"Acute Decompensated Heart Failure","Heart Failure",[338],"biomarkers",{"date":340,"type":36},"2025-08-12",{"date":342,"type":4},"2005-12",{"date":344,"type":21},"2027-12",{"name":42,"class":43},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":195,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":44},"100114995","circulating-markers-for-ischemic-heart-disease-100114995","NCT00762333","Circulating Markers for Ischemic Heart Disease","Inclusion Criteria:\n\n* men and women, 18 years of age and over with acute myocardial infarction (determined by positive cardiac markers -CKMB\u002F troponin) with or without heart failure (dyspnea, rales, edema, elevated jugular venous pressure, ascites).\n* Heart failure can be diagnosed using imaging evidence such as dilated heart, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures\n* A control group of male subjects age 60 and older without history of MI or heart disease\n\nExclusion Criteria:\n\n* Subjects unable to give consent\n* Subjects who have undergone cardiac or non-cardiac surgery in the 3 months prior to enrollment",{"count":353,"type":21},550,"The purpose of this research is to determine if two proteins in the blood are increased during acute myocardial infarction and whether their levels are higher in those who develop heart failure than those who do not. These two proteins are produced and potentially released when the heart muscle is damaged. They may then be released into the blood and be detected by standard method in the research laboratory. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or myocardial infarction.",[314,316,356],"Congestive Heart Failure",{"date":340,"type":36},{"date":359,"type":4},"2007-06",{"date":361,"type":21},"2027-03",{"name":42,"class":43},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":195,"sex":370,"minAge":243,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":373,"conditions":374,"keywords":377,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":44},"100599364","bone-loss-physical-function-and-frailty-in-older-women-with-sickle-cell-trait-sickle-cell-trait-100599364","NCT07083531","Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait","Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait","Inclusion Criteria:\n\n* Female of African Decent.\n* Age 50 years or older.\n* Lack of menstrual period for at least 12 consecutive months\n\nExclusion Criteria:\n\n* Taking medications known to influence bone metabolism (e.g., glucocorticoids, hormonal therapy, cancer or chemotherapy meds, anti-resorptive medications or anabolic therapies).\n* Known metabolic bone disorder (e.g., uncontrolled thyroid disease, hyperparathyroidism, Vitamin D deficiency)\n* Taking an investigational drug\n* Documented sickle cell disease","FEMALE",{"count":372,"type":21},50,"This is a cross-sectional, clinical research study comparing postmenopausal women of African Descent (AD) with different hemoglobin genotypes: normal and sickle cell trait (SCT). This research study has two purposes. The first purpose is to determine whether having SCT is a risk factor for the development of bone thinning in older women. The second purpose is to investigate whether women with SCT have reduced muscle function and increased frailty compared to women without SCT. The investigators estimate enrolling 50 female volunteers who are at least 50 years old and have not had a menstrual period for at least 12 consecutive months. Volunteers need not know whether they have SCT as this will be evaluated as part of the study.",[375,376],"Sickle Cell Disease","Sickle Cell Trait",[378,379],"Sickle Cell Disease (SCD)","Sickle Cell Trait (SCT)","2025-07-16",{"date":382,"type":36},"2025-07-24",{"date":384,"type":36},"2022-08-23",{"date":386,"type":21},"2025-08-23",{"name":42,"class":43},{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":195,"sex":17,"minAge":396,"maxAge":397,"enrollmentInfo":398,"targetDuration":4,"studyType":22,"phases":399,"briefSummary":400,"conditions":401,"keywords":404,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":44},"100524144","managing-anxiety-in-pediatric-primary-care-mapp-100524144","NCT06104904","Managing Anxiety in Pediatric Primary Care (MAPP)","Enhancing the Capacity of Pediatric Primary Care Providers: a Pilot Trial of Anxiety Action Plan","MAPP","Inclusion Criteria for youth:\n\n* 6-17 years of age\n* Have elevated anxiety symptoms as indicated by a total Screen for Child Anxiety Rated Disorders score between 20 and 55 based on parent and\u002For child report\n\nExclusion Criteria for youth:\n\n* Have a medical or psychiatric condition contraindicating participation (e.g., suicidality) based on clinical interview\n* Are receiving psychosocial mental health treatment for anxiety\n\nInclusion Criteria for PCPs:\n\n* PCPs must have a PA, RN, NP, APRN or MD degree and be at least a part time employee in a primary care setting. There are no other inclusion\u002Fexclusion criteria.","6 Years","17 Years",{"count":220,"type":21},[57],"The goal of this clinical trial is to conduct a randomized controlled trial to enhance the capacity of pediatric primary care providers to assist their patients who struggle with anxiety.\n\nThe study aims to refine and assess the feasibility of the Anxiety Action Plan (AxAP), a brief intervention to reduce pediatric anxiety, delivered by primary care providers (PCPs) in community pediatric primary care clinics. The goal of the AxAP is to enhance the capacity of PCPs to identify and intervene with anxious youth, which will enhance access to care in general and especially in locations with few mental health specialists. PCPs participating in this study will attend a training, administer the intervention to enrolled youth assigned to the MAPP condition, participate in coaching sessions, and fill out study questionnaires. Families participating in this study will complete evaluations with the study team, receive the intervention from their PCP (if assigned to the MAPP condition), and fill out study questionnaires. Researchers will compare the MAPP intervention to Enhanced Usual Care (EUC; consisting of videos, handouts, and other resources for anxiety reduction) to see the differences, if any, in child outcomes.",[402,403],"Anxiety","Anxiety Disorders",[402],"2024-12-04",{"date":407,"type":36},"2024-12-09",{"date":409,"type":36},"2023-11-20",{"date":411,"type":21},"2026-01-31",{"name":42,"class":43},{"id":414,"slug":415,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":11,"sex":17,"minAge":420,"maxAge":421,"enrollmentInfo":422,"targetDuration":4,"studyType":22,"phases":424,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":440},"100415762","efficacy-trial-of-the-calm-intervention-100415762","NCT04693858","Efficacy Trial of the CALM Intervention","Enhancing the Capacity of School Nurses to Reduce Excessive Anxiety in Children: an Efficacy Trial of the CALM Intervention","Student Inclusion Criteria:\n\n* Be between the ages of 5-12\n* Have elevated anxiety symptoms as indicated by a) a total SCARED score of 15 or higher based on parent and\u002For child report using the full SCARED from the baseline evaluation, and\u002For b) a Clinician Severity Rating of 3 or higher on any anxiety diagnosis from the Anxiety Disorders Interview Schedule for Children DSM-V (ADIS)\n* Be fluent in English in order to provide informed consent and assent for their participation and to complete the study measures.\n* Children on a stable dose of pharmacological\u002Fpsychotherapeutic treatment will be eligible as long as the dose has been stable for at least 4 weeks and no changes are considered for the duration of the intervention phase of the study (8 weeks)\n\nStudent Exclusion Criteria:\n\n* Children who do not meet the inclusion criteria\n\nNurse Inclusion Criteria:\n\n* Nurses must be a Registered Nurse (RN) or another similar medical professional\n* Nurses must be work in the role of a school nurse\n* Nurses must be fluent in English","5 Years","12 Years",{"count":423,"type":21},218,[57],"Excessive anxiety among elementary students is highly prevalent and associated with impairment in academic, social, and behavioral functioning. The primary aim of this project is to evaluate the initial efficacy of a brief nurse-delivered intervention (CALM: Child Anxiety Learning Modules), relative to a credible comparison (CALM-R, relaxation skills only) and a waitlist control for reducing anxiety symptoms and improving education outcomes at post intervention and at a 1-year follow-up. In addition, the research team will assess the cost effectiveness of CALM versus CALM-R and the waitlist control and examine potential predictors, moderators, and mediators of CALM's impact on child outcomes based on the proposed theory of change.",[427],"Anxiety Disorder of Childhood",[402,429,430,431,432,433],"Child anxiety","School-based interventions","School nursing","Brief anxiety interventions","Cognitive-behavioral therapy",{"date":407,"type":36},{"date":436,"type":36},"2020-12-01",{"date":438,"type":21},"2026-07-30",{"name":42,"class":43},2,{"id":442,"slug":443,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":195,"sex":17,"minAge":448,"maxAge":449,"enrollmentInfo":450,"targetDuration":4,"studyType":22,"phases":452,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":44},"100567438","effect-of-force-magnitude-on-canine-retraction-and-gingival-crevicular-fluid-proteome-100567438","NCT06668194","Effect of Force Magnitude on Canine Retraction and Gingival Crevicular Fluid Proteome","A Randomized Clinical Trial Comparing the Effect of Force Magnitude on the Rate of Canine Retraction and Gingival Crevicular Fluid Proteome Profile","Inclusion Criteria:\n\n* Healthy patient, non-smoker\n* Age: 11 - 16 years of age, inclusive.\n* A full complement of dentition (central incisor to 1st molar) in the four quadrants, except second molars\n* Patients requiring at least upper bilaterally maxillary 1st premolar extraction as a treatment plan (Class I bimaxillary protrusion\u002F crowding or Class II maxillary dentoalveolar protrusion\u002F crowding)\n* At least 5 mm of space left between canine and 2nd premolar to be closed at the time of canine retraction\n* At least six months after the extraction of first premolars and in a 0.019 x 0.025-inch stainless steel archwire in the maxilla\n* The ability to read and understand English and to provide informed consent\n\nExclusion Criteria:\n\n* Patients under 11 years of age and over the age of 16.\n* Non-extraction treatment plan\n* Extraction of maxillary tooth other than first premolars bilaterally.\n* Evidence of poor oral hygiene\n* Evidence of previous root resorption\n* Missing or impacted tooth in any of the quadrant except 3rd molars.\n* Medical issues that affect tooth movement\n* Inability to provide oral and written consent to participate.\n* Patient on medications that may alter bone metabolisms like bisphosphonates, oral contraceptives, or PTH (parathyroid hormone)\n* Chronic illness or syndromic patients.\n* Pregnant women, prisoners, and decisional impaired","11 Years","16 Years",{"count":451,"type":21},40,[57],"This study aims to examine the effect of force levels in orthodontic treatment during canine retraction. Force levels refer to the pressure applied by the orthodontic devices to move teeth. Data collection will include gingival fluid, dental molds from a digital scanner, and x-rays of the upper canine region on both sides of the mouth during treatment. The null hypothesis to be tested is that there is no significant difference in the rate of canine movement between the light force and the heavy force levels.",[455],"Tooth Crowding",[457,458,459,460],"Orthodontic space closure","Canine retraction","Gingival crevicular fluid","Proteomics","2024-11-23",{"date":463,"type":36},"2024-11-26",{"date":465,"type":36},"2024-11-13",{"date":467,"type":21},"2028-04-01",{"name":42,"class":43},""]